Verus Financial Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $507K | Buy |
2,013
+5
| +0.2% | +$1.08K | 0.04% | 75 |
|
|
2026
Q1 | $420K | Sell |
2,008
-31
| -2% | -$6.88K | 0.04% | 81 |
|
|
2025
Q4 | $450K | Sell |
2,039
-602
| -23% | -$137K | 0.04% | 74 |
|
|
2025
Q3 | $611K | Buy |
2,641
+5
| +0.2% | +$1.02K | 0.06% | 57 |
|
|
2025
Q2 | $502K | Buy |
2,636
+5
| +0.2% | +$929 | 0.05% | 61 |
|
|
2025
Q1 | $465K | Sell |
2,631
-854
| -25% | -$166K | 0.05% | 53 |
|
|
2024
Q4 | $610K | Buy |
3,485
+6
| +0.2% | +$1.1K | 0.07% | 48 |
|
|
2024
Q3 | $685K | Sell |
3,479
-13
| -0.4% | -$2.43K | 0.08% | 47 |
|
|
2024
Q2 | $599K | Sell |
3,492
-183
| -5% | -$30.3K | 0.07% | 46 |
|
|
2024
Q1 | $669K | Buy |
3,675
+5
| +0.1% | +$862 | 0.08% | 46 |
|
|
2023
Q4 | $603K | Buy |
3,670
+373
| +11% | +$54.4K | 0.07% | 51 |
|
|
2023
Q3 | $488K | Buy |
3,297
+605
| +22% | +$88.8K | 0.06% | 54 |
|
|
2023
Q2 | $381K | Sell |
2,692
-745
| -22% | -$109K | 0.05% | 63 |
|
|
2023
Q1 | $507K | Sell |
3,437
-137
| -4% | -$20.9K | 0.07% | 58 |
|
|
2022
Q4 | $528K | Sell |
3,574
-63
| -2% | -$9.66K | 0.07% | 56 |
|
|
2022
Q3 | $526K | Buy |
3,637
+827
| +29% | +$119K | 0.08% | 57 |
|
|
2022
Q2 | $415K | Buy |
2,810
+5
| +0.2% | +$764 | 0.06% | 60 |
|
|
2022
Q1 | $469K | Sell |
2,805
-525
| -16% | -$76.3K | 0.07% | 55 |
|
|
2021
Q4 | $451K | Buy |
3,330
+1
| +0% | +$118 | 0.06% | 55 |
|
|
2021
Q3 | $358K | Sell |
3,329
-481
| -13% | -$55K | 0.05% | 66 |
|
|
2021
Q2 | $442K | Buy |
3,810
+219
| +6% | +$24.7K | 0.07% | 54 |
|
|
2021
Q1 | $378K | Sell |
3,591
-499
| -12% | -$53.4K | 0.06% | 60 |
|
|
2020
Q4 | $438K | Buy |
+4,090
| New | +$393K | 0.08% | 48 |
|
|
2020
Q3 | – | Sell |
-3,225
| Closed | -$317K | – | 174 |
|
|
2020
Q2 | $317K | Sell |
3,225
-207
| -6% | -$18.2K | 0.07% | 54 |
|
|
2020
Q1 | $261K | Buy |
3,432
+179
| +6% | +$15.2K | 0.08% | 57 |
|
|
2019
Q4 | $288K | Buy |
3,253
+11
| +0.3% | +$913 | 0.09% | 55 |
|
|
2019
Q3 | $245K | Buy |
3,242
+456
| +16% | +$31.3K | 0.08% | 58 |
|
|
2019
Q2 | $203K | Buy |
2,786
+154
| +6% | +$12.1K | 0.07% | 54 |
|
|
2019
Q1 | $212K | Buy |
2,632
+8
| +0.3% | +$654 | 0.07% | 50 |
|
|
2018
Q4 | $248K | Hold |
2,624
| – | – | 0.09% | 42 |
|
|
2018
Q3 | $248K | Buy |
2,624
+3
| +0.1% | +$284 | 0.09% | 42 |
|
|
2018
Q2 | $243K | Buy |
2,621
+3
| +0.1% | +$293 | 0.09% | 40 |
|
|
2018
Q1 | $248K | Sell |
2,618
-37
| -1% | -$4.07K | 0.09% | 42 |
|
|
2017
Q4 | $257K | Sell |
2,655
-32
| -1% | -$3.02K | 0.09% | 43 |
|
|
2017
Q3 | $239K | Buy |
+2,687
| New | +$205K | 0.09% | 42 |
|
Other funds holding ABBV
Verus Financial Partners's ABBV Position: Q2 2026 in Review
Verus Financial Partners increased its AbbVie (ABBV) stake by 0.25% in Q2 2026, buying an estimated $1.08K and bringing the position to 2,013 shares worth $507K. The position accounts for 0.04% of the portfolio, ranked #75.
Verus Financial Partners first reported a position in ABBV in Q3 2017 and has held it in 35 quarters since. The position peaked at $685K in Q3 2024. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Verus Financial Partners held 2,013 shares of AbbVie worth $507K as of Q2 2026.
- Verus Financial Partners bought 5 AbbVie shares in Q2 2026, an estimated $1.08K.
- AbbVie made up 0.04% of Verus Financial Partners's portfolio in Q2 2026, its #75 holding.
- Verus Financial Partners first reported a position in AbbVie in Q3 2017 and has held it in 35 quarters since.
- Verus Financial Partners's AbbVie position peaked at $685K in Q3 2024.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Verus Financial Partners's 13F filing for Q2 2026, filed 21 Jul 2026.